Abstract：
Pheochromocytomas are rare tumours originating in chromaffin cells, representing 0.1%-1% of all secondary hypertension cases. The majority are benign and unilateral, characterised by the production of catecholamines and other neuropeptides. Mainly located in the adrenal gland, they are more frequent between the third and fifth decades of life. Iodine-131 metaiodobenzylguanidine (131I-MIBG), a radiopharmaceutical agent used for scintigraphic localisation of pheochromocytomas, has been employed to treat malignant pheochromocytomas since 1983 in a few specialised centres around the world. We reviewed our clinical experience in one such case of a young lady who presented with history of abdominal pain, headache and lower back pain. On evaluation, ultrasonography revealed a right adrenal mass and elevated urine vanillylmandelic acid levels. Following surgical resection and histopathological confirmation of pheochromocytoma, MIBG scintigraphy revealed osseous metastases and hence, she underwent 131I-MIBG therapy.
摘要：
嗜铬细胞瘤是起源于染色质细胞的罕见肿瘤，占所有继发性高血压病例的0.1%-1%。大多数是良性和单方面的，以产生儿茶酚胺和其他神经肽为特征。主要位于肾上腺,它们在生命的第三个和第五个十年之间更加频繁。碘-131间碘苄基胍（131I-MIBG），一种用于嗜铬细胞瘤闪烁显像定位的放射性药物，自1983年以来，已在世界各地的一些专业中心用于治疗恶性嗜铬细胞瘤。我们回顾了我们在一例有腹痛史的年轻女士中的临床经验，头痛和下背部疼痛。关于评估，超声检查显示右侧肾上腺肿块和尿香草扁桃酸水平升高。在手术切除和组织病理学确认嗜铬细胞瘤后，MIBG闪烁显像显示骨转移，因此，她接受了131I-MIBG治疗.
